NASDAQ:CTIC CTI BioPharma (CTIC) Stock Forecast, Price & News $9.04 -0.01 (-0.11%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$9.04▼$9.0550-Day Range$4.08▼$9.0552-Week Range$4.01▼$9.06Volume1.58 million shsAverage Volume11.18 million shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$10.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CTI BioPharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.8% Upside$10.29 Price TargetShort InterestHealthy6.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector453rd out of 981 stocksPharmaceutical Preparations Industry213th out of 482 stocks 3.3 Analyst's Opinion Consensus RatingCTI BioPharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.29, CTI BioPharma has a forecasted upside of 13.8% from its current price of $9.04.Amount of Analyst CoverageCTI BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of CTI BioPharma have been sold short.Short Interest Ratio / Days to CoverCTI BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CTI BioPharma has recently decreased by 33.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCTI BioPharma does not currently pay a dividend.Dividend GrowthCTI BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTIC. Previous Next 1.8 News and Social Media Coverage News SentimentCTI BioPharma has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CTI BioPharma this week, compared to 3 articles on an average week.Search InterestOnly 15 people have searched for CTIC on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows8 people have added CTI BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CTI BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of CTI BioPharma is held by insiders.Percentage Held by Institutions99.40% of the stock of CTI BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CTI BioPharma are expected to grow in the coming year, from ($0.25) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CTI BioPharma is -15.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CTI BioPharma is -15.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About CTI BioPharma (NASDAQ:CTIC) StockCTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.Read More Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CTIC Stock News HeadlinesJune 7, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was upgraded to a Hold Rating at Stifel NicolausJune 5, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on CTI BioPharma (NASDAQ:CTIC)June 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 30, 2023 | markets.businessinsider.comStifel Nicolaus upgrades CTI BioPharma (CTIC) to a HoldMay 28, 2023 | americanbankingnews.comCTI BioPharma (NASDAQ:CTIC) Now Covered by Analysts at StockNews.comMay 25, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 25, 2023 | finance.yahoo.comSobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 24, 2023 | msn.comJMP Securities Maintains CTI BioPharma (CTIC) Market Perform RecommendationJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 24, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)May 20, 2023 | americanbankingnews.comCTI BioPharma Corp. (NASDAQ:CTIC) to Post Q2 2023 Earnings of ($0.06) Per Share, Brookline Capital Management ForecastsMay 19, 2023 | americanbankingnews.comFY2024 EPS Estimates for CTI BioPharma Corp. (NASDAQ:CTIC) Cut by AnalystMay 19, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for CTI BioPharma Corp.'s FY2026 Earnings (NASDAQ:CTIC)May 16, 2023 | msn.comCTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go ThroughMay 16, 2023 | msn.comSVB Leerink Downgrades CTI BioPharma (CTIC)May 16, 2023 | markets.businessinsider.comSVB Securities downgrades CTI BioPharma (CTIC) to a HoldMay 16, 2023 | americanbankingnews.comCTI BioPharma (NASDAQ:CTIC) Cut to Market Perform at SVB SecuritiesMay 16, 2023 | americanbankingnews.comBrokerages Set CTI BioPharma Corp. (NASDAQ:CTIC) PT at $10.50May 16, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates CTI BioPharma Corp.May 15, 2023 | msn.comStifel Downgrades CTI BioPharma (CTIC)May 15, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for CTI BioPharmaMay 15, 2023 | americanbankingnews.comCTI BioPharma (NASDAQ:CTIC) Rating Lowered to Hold at Stifel NicolausMay 12, 2023 | msn.comNeedham Downgrades CTI BioPharma (CTIC)May 12, 2023 | americanbankingnews.comCTI BioPharma (NASDAQ:CTIC) Lowered to "Market Perform" at JMP SecuritiesMay 12, 2023 | americanbankingnews.comLake Street Capital Downgrades CTI BioPharma (NASDAQ:CTIC) to HoldMay 12, 2023 | msn.comUnusual Call Option Trade in CTI BioPharma (CTIC) Worth $312.39KMay 12, 2023 | americanbankingnews.comCTI BioPharma (NASDAQ:CTIC) Stock Rating Lowered by Needham & Company LLCSee More Headlines CTIC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTIC Company Calendar Last Earnings3/06/2023Today6/07/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees22Year Founded1992Price Target and Rating Average Stock Price Forecast$10.29 High Stock Price Forecast$13.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+13.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.57Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.19 billion OptionableOptionable Beta0.83 Social Links Key ExecutivesAdam R. CraigPresident, CEO, Director & Chief Medical OfficerDavid H. KirskeCFO, Secretary & Executive Vice PresidentJim FongChief Commercial Officer & Executive VPJohn VolponeChief of Staff & Executive Vice PresidentKey CompetitorsStructure TherapeuticsNASDAQ:GPCRCrinetics PharmaceuticalsNASDAQ:CRNXOPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDAvadel PharmaceuticalsNASDAQ:AVDLView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundSold 16,430 shares on 5/18/2023Ownership: 0.037%Geode Capital Management LLCBought 116,026 shares on 5/16/2023Ownership: 1.539%Squarepoint Ops LLCBought 75,016 shares on 5/16/2023Ownership: 0.081%AQR Capital Management LLCBought 3,430 shares on 5/16/2023Ownership: 0.030%Jane Street Group LLCBought 17,500 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CTIC Stock - Frequently Asked Questions Should I buy or sell CTI BioPharma stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTIC shares. View CTIC analyst ratings or view top-rated stocks. What is CTI BioPharma's stock price forecast for 2023? 10 analysts have issued 1-year price objectives for CTI BioPharma's stock. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's share price to reach $10.29 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View analysts price targets for CTIC or view top-rated stocks among Wall Street analysts. How have CTIC shares performed in 2023? CTI BioPharma's stock was trading at $6.01 at the start of the year. Since then, CTIC stock has increased by 50.4% and is now trading at $9.04. View the best growth stocks for 2023 here. Are investors shorting CTI BioPharma? CTI BioPharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 8,080,000 shares, a decline of 33.6% from the April 30th total of 12,170,000 shares. Based on an average daily trading volume, of 5,760,000 shares, the days-to-cover ratio is currently 1.4 days. View CTI BioPharma's Short Interest. When is CTI BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CTIC earnings forecast. How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) posted its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analysts' expectations of $24.88 million. During the same period in the prior year, the business earned ($0.38) earnings per share. What ETFs hold CTI BioPharma's stock? ETFs with the largest weight of CTI BioPharma (NASDAQ:CTIC) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Vanguard U.S. Momentum Factor ETF (VFMO), When did CTI BioPharma's stock split? CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is James A. Bianco's approval rating as CTI BioPharma's CEO? 8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN). What is CTI BioPharma's stock symbol? CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC." Who are CTI BioPharma's major shareholders? CTI BioPharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (9.43%), Rubric Capital Management LP (6.80%), BlackRock Inc. (5.39%), Stonepine Capital Management LLC (4.96%), Bain Capital Life Sciences Investors LLC (3.57%) and Bank of America Corp DE (2.66%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, James K Fong, Michael A Metzger and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of CTI BioPharma? Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CTI BioPharma's stock price today? One share of CTIC stock can currently be purchased for approximately $9.04. How much money does CTI BioPharma make? CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.19 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How can I contact CTI BioPharma? CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206. This page (NASDAQ:CTIC) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.